186 related articles for article (PubMed ID: 26087292)
1. Gene Expression Signature in Adipose Tissue of Acromegaly Patients.
Hochberg I; Tran QT; Barkan AL; Saltiel AR; Chandler WF; Bridges D
PLoS One; 2015; 10(6):e0129359. PubMed ID: 26087292
[TBL] [Abstract][Full Text] [Related]
2. The possible role of mRNA expression changes of GH/IGF-1/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly.
Touskova V; Klouckova J; Durovcova V; Lacinova Z; Kavalkova P; Trachta P; Kosak M; Mraz M; Haluzikova D; Hana V; Marek J; Krsek M; Haluzik M
Physiol Res; 2016 Jul; 65(3):493-503. PubMed ID: 27070751
[TBL] [Abstract][Full Text] [Related]
3. Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly.
Arlien-Søborg MC; Dal J; Madsen MA; Høgild ML; Hjelholt AJ; Pedersen SB; Møller N; Jessen N; Jørgensen JOL
EBioMedicine; 2022 Jan; 75():103763. PubMed ID: 34929488
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of insulin-like growth factor binding protein-3 levels to determine acromegaly activity and effectiveness of transsphenoidal pituitary surgery.
Ochoa R; Mercado M; Chacón X; Fonseca E; Hernández M; Zárate A
Arch Med Res; 1999; 30(4):303-6. PubMed ID: 10573632
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in acromegaly.
Falch CM; Arlien-Søborg MC; Dal J; Sundaram AYM; Michelsen AE; Ueland T; Olsen LG; Heck A; Bollerslev J; Jørgensen JOL; Olarescu NC
Eur J Endocrinol; 2023 Mar; 188(3):. PubMed ID: 36895180
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy?
Beuschlein F; Hancke K; Petrick M; Göbel H; Honegger J; Reincke M
Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):214-8. PubMed ID: 15891957
[TBL] [Abstract][Full Text] [Related]
7. Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment.
Dal J; Høyer KL; Pedersen SB; Magnusson NE; Bjerring P; Frystyk J; Møller N; Jessen N; Jørgensen JO
J Clin Endocrinol Metab; 2016 Oct; 101(10):3716-3723. PubMed ID: 27466699
[TBL] [Abstract][Full Text] [Related]
8. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments.
Ramos-Leví AM; Marazuela M; Paniagua A; Quinteiro C; Riveiro J; Álvarez-Escolá C; Lúcas T; Blanco C; de Miguel P; Martínez de Icaya P; Pavón I; Bernabeu I
Eur J Endocrinol; 2015 Feb; 172(2):115-22. PubMed ID: 25385818
[TBL] [Abstract][Full Text] [Related]
9. Is there any relation between hyperinsulinemia, insulin resistance and colorectal lesions in patients with acromegaly?
Foltyn W; Kos-Kudla B; Strzelczyk J; Matyja V; Karpe J; Rudnik A; Marek B; Kajdaniuk D; Sieron A; Latos W
Neuro Endocrinol Lett; 2008 Feb; 29(1):107-12. PubMed ID: 18283256
[TBL] [Abstract][Full Text] [Related]
10. Serum leptin levels in acromegaly--a significant role for adipose tissue and fasting insulin/glucose ratio.
Bolanowski M; Milewicz A; Bidzińska B; Jedrzejuk D; Daroszewski J; Mikulski E
Med Sci Monit; 2002 Oct; 8(10):CR685-9. PubMed ID: 12388920
[TBL] [Abstract][Full Text] [Related]
11. Insulin action in human adipose tissue in acromegaly.
Bolinder J; Ostman J; Werner S; Arner P
J Clin Invest; 1986 Apr; 77(4):1201-6. PubMed ID: 3514677
[TBL] [Abstract][Full Text] [Related]
12. Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.
Reyes-Vidal CM; Mojahed H; Shen W; Jin Z; Arias-Mendoza F; Fernandez JC; Gallagher D; Bruce JN; Post KD; Freda PU
J Clin Endocrinol Metab; 2015 Aug; 100(8):2946-55. PubMed ID: 26037515
[TBL] [Abstract][Full Text] [Related]
13. Markers of function and proliferation in non-invasive and invasive bi- and plurihormonal adenomas of patients with acromegaly: an immunohistochemical study.
Müller W; Saeger W; Wellhausen L; Derwahl KM; Hamacher C; Lüdecke DK
Pathol Res Pract; 1999; 195(9):595-603. PubMed ID: 10507079
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities.
Olarescu NC; Ueland T; Godang K; Lindberg-Larsen R; Jørgensen JO; Bollerslev J
Eur J Endocrinol; 2014 Jan; 170(1):39-48. PubMed ID: 24092547
[TBL] [Abstract][Full Text] [Related]
15. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
16. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
Matta MP; Couture E; Cazals L; Vezzosi D; Bennet A; Caron P
Eur J Endocrinol; 2008 Mar; 158(3):305-10. PubMed ID: 18299462
[TBL] [Abstract][Full Text] [Related]
17. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
18. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly.
Ueland T; Fougner SL; Godang K; Lekva T; Schurgers LJ; Scholz H; Halvorsen B; Schreiner T; Aukrust P; Bollerslev J
J Clin Endocrinol Metab; 2010 Jan; 95(1):361-8. PubMed ID: 19880791
[TBL] [Abstract][Full Text] [Related]
19. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
20. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
